Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2018 May:11:137-144.
doi: 10.1016/j.molmet.2018.02.005. Epub 2018 Feb 20.

Statin dose reduction with complementary diet therapy: A pilot study of personalized medicine

Affiliations
Randomized Controlled Trial

Statin dose reduction with complementary diet therapy: A pilot study of personalized medicine

Bianca Scolaro et al. Mol Metab. 2018 May.

Abstract

Objective: Statin intolerance, whether real or perceived, is a growing issue in clinical practice. Our aim was to evaluate the effects of reduced-dose statin therapy complemented with nutraceuticals.

Methods: First phase: Initially, 53 type 2 diabetic statin-treated patients received a supplementation with fish oil (1.7 g EPA + DHA/day), chocolate containing plant sterols (2.2 g/day), and green tea (two sachets/day) for 6 weeks. Second phase: "Good responders" to supplementation were identified after multivariate analysis (n = 10), and recruited for a pilot protocol of statin dose reduction. "Good responders" were then provided with supplementation for 12 weeks: standard statin therapy was kept during the first 6 weeks and reduced by 50% from weeks 6-12.

Results: First phase: After 6 weeks of supplementation, plasma LDL-C (-13.7% ± 3.7, P = .002) and C-reactive protein (-35.5% ± 5.9, P = .03) were reduced. Analysis of lathosterol and campesterol in plasma suggested that intensity of LDL-C reduction was influenced by cholesterol absorption rate rather than its synthesis. Second phase: no difference was observed for plasma lipids, inflammation, cholesterol efflux capacity, or HDL particles after statin dose reduction when compared to standard therapy.

Conclusions: Although limited by the small sample size, our study demonstrates the potential for a new therapeutic approach combining lower statin dose and specific dietary compounds. Further studies should elucidate "good responders" profile as a tool for personalized medicine. This may be particularly helpful in the many patients with or at risk for CVD who cannot tolerate high dose statin therapy.

Trial registration: ClinicalTrials.gov, NCT02732223.

Keywords: Atherosclerosis; Omega-3 fatty acids; Plant sterols; Polyphenols; Responders.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Baseline sterol profile (Mean ± SEM) of subgroups divided according to the intensity of LDL-C reduction (above or below the median; MED = −13%) after treatment with nutraceuticals. P values were obtained by T-test for independent groups. n = 23 in each group.

Similar articles

Cited by

References

    1. Gotto A.M., Moon J.E. Pharmacotherapies for lipid modification: beyond the statins. Nature Reviews Cardiology. 2013;10:560–570. - PubMed
    1. Libby P., Ridker P.M., Hansson G.K. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473:317–325. - PubMed
    1. Sabatine M.S., Giugliano R.P., Keech A.C., Honarpour N., Wiviott S.D., Murphy S.A. Evolocumab and clinical outcomes in patients with cardiovascular disease. New England Journal of Medicine. 2017;376:1713–1722. - PubMed
    1. Nicholls S.J., Puri R., Anderson T., Ballantyne C.M., Cho L., Kastelein J.J.P. Effect of evolocumab on progression of coronary disease in statin-treated patients. JAMA. 2016;316(22):2373. - PubMed
    1. Parathath S., Grauer L., Huang L.-S., Sanson M., Distel E., Goldberg I.J. Diabetes adversely affects macrophages during atherosclerotic plaque regression in mice. Diabetes. 2011;60:1759–1769. - PMC - PubMed

Publication types

MeSH terms

Substances

Associated data